With 0.16 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.15 million shares. During the session, the Medical Instruments & Supplies company that operates in wider Healthcare sector, reached to the highest price of $6.28 whereas the lowest price it dropped to was $6.09. The 52-week range on INFU shows that it touched its highest point at $9.97 and its lowest point at $4.61 during that stretch. It currently has a 1-year price target of $13.62. Beta for the stock currently stands at 1.81.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of INFU was up-trending over the past week, with a rise of 1.64%, but this was up by 1.14% over a month. Three-month performance surged to 8.22% while six-month performance fell -30.53%. The stock lost -6.35% in the past year, while it has lost -26.75% so far this year. A look at the trailing 12-month EPS for INFU yields 0.15 with Next year EPS estimates of 0.30. For the next quarter, that number is 0.04. This implies an EPS growth rate of 36.36% for this year and 98.33% for next year.
Float and Shares Shorts:
At present, 20.97 million INFU shares are outstanding with a float of 18.96 million shares on hand for trading. On 2025-05-30, short shares totaled 0.51 million, which was 242.0 higher than short shares on 1745971200. In addition to Ms. Carrie A. Lachance B.S.N., M.B.A., R.N. as the firm’s President, CEO & Director, Mr. Barry G. Steele CPA serves as its Executive VP & CFO.
Institutional Ownership:
Through their ownership of 0.78529 of INFU’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, INFU reported revenue of $34716000.0 and operating income of $618000.0. The EBITDA in the recently reported quarter was $3909000.0 and diluted EPS was -$0.01.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With INFU analysts setting a high price target of 15.0 and a low target of 12.0, the average target price over the next 12 months is 14.0. Based on these targets, INFU could surge 142.33% to reach the target high and rise by 93.86% to reach the target low. Reaching the average price target will result in a growth of 126.17% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $0.14375 being high and $0.14167 being low. For INFU, this leads to a yearly average estimate of $0.1425. Based on analyst estimates, the high estimate for the next quarter is $0.06 and the low estimate is $0.06. The average estimate for the next quarter is thus $0.06.
